- Tytuł:
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet Oncology June 2019 20(6):781-794
Czasopismo naukowe